Evofem Biosciences Announces Peer-Reviewed Publication of the Pivotal Phase 3 AMPOWER Study Results For Phexxi™ (lactic acid, citric acid and potassium bitartrate) in Contraception
About Evofem Biosciences, Inc.
- NASDAQ: $EVFM
- Notified: $3.07
- 08:31 EDT
